First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in the Brains of Healthy Controls and Patients With Dementia.
This is a first in human study that will assess the safety and diagnostic performance of \[18F\]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent. This agent has the potential to identify the early changes that occur in the brains of patients with Alzheimer's disease (AD) and frontotemporal dementia (FTD).
• Age 40-75
• Age-suitable BMI
• Ability to provide written informed consent and willingly comply with protocol requirements or has a legal authorized representative/guardian who provides surrogate informed consent.
• No apparent physical disorder.
• Radial, ulnar, or brachial artery suitable for catheterization.
• Non-smoker, and not taking OTC nicotine cessation - to limit peripheral metabolism events.
• Devoid of CNS prescription drugs for three weeks - to limit peripheral metabolism events.
• For Cohort 2B and 2C:
• Must have a study partner (informant) who spends a minimum average of 5 hours per week with the participant (e.g. family member, significant other, friend, caregiver), is generally aware of the participant's daily activities, can provide information about the participant's cognitive and functional performance, and will accompany the participant in all study procedure.
• Recent (within 6 mo.) MME clinical scores.